Literature DB >> 20390492

Improvements in physical wellbeing over the first two years on antiretroviral therapy in western Kenya.

Matthew P Fox1, Kelly McCoy, Bruce A Larson, Sydney Rosen, Margaret Bii, Carolyne Sigei, Douglas Shaffer, Fred Sawe, Monique Wasunna, Jonathon L Simon.   

Abstract

Improvements in physical wellbeing during the first six months on antiretroviral therapy (ART) are well known, but little is known regarding long-term follow-up. We conducted a prospective cohort study among 222 HIV-positive adult tea plantation workers in western Kenya to assess wellbeing over their first two years on ART. Study subjects completed a standardized questionnaire during repeat ART clinic visits. A 30-day recall period was used to elicit the number of days when subjects experienced poor health and the number of days that pain made it difficult to complete usual activities at home and work. A seven-day recall period was used to assess the severity of bodily pain, nausea, fatigue, and rash. Prevalence of most symptoms declined over time. A median of seven days poor health during the first month on ART declined to three days in the 24th month (p=0.043). For pain making usual activities difficult, a median of seven days during the first month on ART fell to zero by 12 months (p< or =0.0001) but increased to three days by two years. Any bodily pain (range 59-83%) and fatigue (range 51-84%) over the past seven days were common through two years. However, pain and fatigue often over the past seven days declined over two years (from 24-10% (p=0.067) and 41-15% (p=0.002)). Skin rash was rare at all times, though higher at two years (8.6%) than any other time. Initial improvements in physical wellbeing were sustained over two years, however, increased pain and skin rash at year two may indicate problems as treatment programs mature. These improvements in physical wellbeing will be important in sustaining the long-term success of HIV treatment programs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20390492      PMCID: PMC2856113          DOI: 10.1080/09540120903038366

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  17 in total

1.  Psychological effects of HAART: a 2-year study.

Authors:  J G Rabkin; S J Ferrando; S H Lin; M Sewell; M McElhiney
Journal:  Psychosom Med       Date:  2000 May-Jun       Impact factor: 4.312

2.  Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal.

Authors:  M Poupard; N F Ngom Gueye; D Thiam; B Ndiaye; P M Girard; E Delaporte; P S Sow; R Landman
Journal:  HIV Med       Date:  2007-03       Impact factor: 3.180

3.  Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa.

Authors:  Sydney Rosen; Mpefe Ketlhapile; Ian Sanne; Mary Bachman Desilva
Journal:  AIDS       Date:  2008-07       Impact factor: 4.177

4.  Short-term physical and emotional health outcomes of public sector ART in the Free State province of South Africa.

Authors:  Edwin Wouters; Herman Meulemans; H C J Van Rensburg; J C Heunis; Dimitri Mortelmans
Journal:  Qual Life Res       Date:  2007-11       Impact factor: 4.147

5.  High prevalence of HIV infection among rural tea plantation residents in Kericho, Kenya.

Authors:  G Foglia; W B Sateren; P O Renzullo; C T Bautista; L Langat; M K Wasunna; D E Singer; P T Scott; M L Robb; D L Birx
Journal:  Epidemiol Infect       Date:  2007-06-29       Impact factor: 2.451

Review 6.  Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act.

Authors:  Robert W Burgoyne; Darrell H S Tan
Journal:  J Antimicrob Chemother       Date:  2008-01-03       Impact factor: 5.790

7.  A further investigation of health-related quality of life over time among men with HIV infection in the HAART era.

Authors:  Huanguang Jia; Constance R Uphold; Yu Zheng; Samuel Wu; G John Chen; Kimberly Findley; Pamela W Duncan
Journal:  Qual Life Res       Date:  2007-04-28       Impact factor: 4.147

8.  Early effects of antiretroviral therapy on work performance: preliminary results from a cohort study of Kenyan agricultural workers.

Authors:  Bruce A Larson; Matthew P Fox; Sydney Rosen; Margaret Bii; Carolyne Sigei; Douglas Shaffer; Fredrick Sawe; Monique Wasunna; Jonathon L Simon
Journal:  AIDS       Date:  2008-01-30       Impact factor: 4.177

9.  Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda.

Authors:  A L Stangl; N Wamai; J Mermin; A C Awor; R E Bunnell
Journal:  AIDS Care       Date:  2007-05

Review 10.  Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review.

Authors:  Sydney Rosen; Matthew P Fox; Christopher J Gill
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

View more
  10 in total

Review 1.  A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy.

Authors:  Kasey R Claborn; Ellen Meier; Mary Beth Miller; Thad R Leffingwell
Journal:  Psychol Health Med       Date:  2014-08-11       Impact factor: 2.423

2.  Health and functional status among older people with HIV/AIDS in Uganda.

Authors:  Francien Scholten; Joseph Mugisha; Janet Seeley; Eugene Kinyanda; Susan Nakubukwa; Paul Kowal; Nirmala Naidoo; Ties Boerma; Somnath Chatterji; Heiner Grosskurth
Journal:  BMC Public Health       Date:  2011-11-24       Impact factor: 3.295

3.  An obese body mass increases the adverse effects of HIV/AIDS on balance and gait.

Authors:  Lance O Bauer; Zhao Wu; Leslie I Wolfson
Journal:  Phys Ther       Date:  2011-04-28

4.  Prevalence and correlates of pain and pain treatment in a western Kenya referral hospital.

Authors:  Kristin T L Huang; Claudio Owino; Gregory P Gramelspacher; Patrick O Monahan; Rebeka Tabbey; Mildred Hagembe; Robert M Strother; Festus Njuguna; Rachel C Vreeman
Journal:  J Palliat Med       Date:  2013-09-13       Impact factor: 2.947

5.  Assessment of the face validity of two pain scales in Kenya: a validation study using cognitive interviewing.

Authors:  Kristin Tl Huang; Claudio Owino; Rachel C Vreeman; Mildred Hagembe; Festus Njuguna; R Matthew Strother; Gregory P Gramelspacher
Journal:  BMC Palliat Care       Date:  2012-07-10       Impact factor: 3.234

6.  Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment.

Authors:  Sydney Rosen; Bruce Larson; Alana Brennan; Lawrence Long; Matthew Fox; Constance Mongwenyana; Mpefe Ketlhapile; Ian Sanne
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

7.  Economic returns to investment in AIDS treatment in low and middle income countries.

Authors:  Stephen Resch; Eline Korenromp; John Stover; Matthew Blakley; Carleigh Krubiner; Kira Thorien; Robert Hecht; Rifat Atun
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

8.  Work and home productivity of people living with HIV in Zambia and South Africa.

Authors:  Ranjeeta Thomas; Rocco Friebel; Kerrie Barker; Lawrence Mwenge; Sarah Kanema; Nosivuyile Vanqa; Abigail Harper; Nomtha Bell-Mandla; Peter C Smith; Sian Floyd; Peter Bock; Helen Ayles; Sarah Fidler; Richard Hayes; Katharina Hauck
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

9.  The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.

Authors:  Gesine Meyer-Rath; Jan Pienaar; Brian Brink; Andrew van Zyl; Debbie Muirhead; Alison Grant; Gavin Churchyard; Charlotte Watts; Peter Vickerman
Journal:  PLoS Med       Date:  2015-09-01       Impact factor: 11.069

10.  What constitutes a palliative care need in people with serious illnesses across Africa? A mixed-methods systematic review of the concept and evidence.

Authors:  Oladayo A Afolabi; Kennedy Nkhoma; Matthew Maddocks; Richard Harding
Journal:  Palliat Med       Date:  2021-04-16       Impact factor: 4.762

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.